Vertex Pharmaceuticals Inc
VRTX
View Detailed Chart
452.040USD
+6.110+1.37%
Close 12/12, 16:00（ET）Quotes delayed by 15 min
114.80BMarket Cap
31.59P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.37%
5 Days
-0.76%
1 Month
+3.41%
6 Months
-0.75%
Year to Date
+12.25%
1 Year
-2.52%
View Detailed Chart
TradingKey Stock Score of Vertex Pharmaceuticals Inc
Currency: USD Updated: 2025-12-12Key Insights
Vertex Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 7/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 489.09.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vertex Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
33
analysts
Buy
Current Rating
489.093
Target Price
+10.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Vertex Pharmaceuticals Inc Highlights
StrengthsRisks
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 23.40% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 31.59, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 249.27M shares, decreasing 0.85% quarter-over-quarter.
Held by Ken Fisher
Star Investor Ken Fisher holds 25.96K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.81.
Vertex Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Vertex Pharmaceuticals Inc Info
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Ticker SymbolVRTX
CompanyVertex Pharmaceuticals Inc
CEOKewalramani (Reshma)
Websitehttps://www.vrtx.com/
FAQs
What is the current price of Vertex Pharmaceuticals Inc (VRTX)?
The current price of Vertex Pharmaceuticals Inc (VRTX) is 452.040.
What is the symbol of Vertex Pharmaceuticals Inc?
The ticker symbol of Vertex Pharmaceuticals Inc is VRTX.
What is the 52-week high of Vertex Pharmaceuticals Inc?
The 52-week high of Vertex Pharmaceuticals Inc is 519.680.
What is the 52-week low of Vertex Pharmaceuticals Inc?
The 52-week low of Vertex Pharmaceuticals Inc is 362.500.
What is the market capitalization of Vertex Pharmaceuticals Inc?
The market capitalization of Vertex Pharmaceuticals Inc is 114.80B.
What is the net income of Vertex Pharmaceuticals Inc?
The net income of Vertex Pharmaceuticals Inc is -535.60M.
Is Vertex Pharmaceuticals Inc (VRTX) currently rated as Buy, Hold, or Sell?
According to analysts, Vertex Pharmaceuticals Inc (VRTX) has an overall rating of Buy, with a price target of 489.093.
What is the Earnings Per Share (EPS TTM) of Vertex Pharmaceuticals Inc (VRTX)?
The Earnings Per Share (EPS TTM) of Vertex Pharmaceuticals Inc (VRTX) is 14.308.
Related Instruments
+1.83%
+0.76%
-0.31%
-0.51%
+0.15%
+1.33%
+0.11%
-0.23%
-2.28%
+0.23%
-0.37%
+2.40%
-0.23%
-0.16%
-0.73%
-0.74%
0.00%
-1.30%
-3.65%Popular Symbols
